FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Erica L. Mayer, MD, MPH
Advertisement
Articles by Erica L. Mayer, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Iberdomide: A New Oral Paradigm in Multiple Myeloma Care
2
FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer
3
Oncology Clinicians Must Prioritize Survivorship Lifestyle Discussions
4
Nursing Protocols for the New Oral RAS Inhibitor Daraxonrasib
5